(4R,5S,6S,7R)-5,6-二羟基-1,3,4,7-四(苯基甲基)-1,3-二氮杂环庚-2-酮 | 153223-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 中文名称: (4R,5S,6S,7R)-5,6-二羟基-1,3,4,7-四(苯基甲基)-1,3-二氮杂环庚-2-酮
• 英文名称: (4R,5S,6S,7R)-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-diazapin-2-one
• 英文别名: XL075；2H-1,3-Diazepin-2-one, hexahydro-5,6-dihydroxy-1,3,4,7-tetrakis(phenylmethyl)-, (4R,5S,6S,7R)-；(4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one
• CAS: 153223-23-5
• 化学式: C₃₃H₃₄N₂O₃
• 分子量: 506.645
• InChiKey: HZUCRWWOEVMAPC-ZRTHHSRSSA-N

物化性质

• 沸点：
  698.4±55.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  64
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R,5S,6S,7R)-5,6-二羟基-1,3,4,7-四(苯基甲基)-1,3-二氮杂环庚-2-酮 在 草酰氯 、 二甲基亚砜 作用下， 以82%的产率得到(4R,5S,7R)-hexahydro-5-hydroxy-1,3,4,7-tetrakis(phenylmethyl)-2H-1,3-diazapine-2,6-dione
  参考文献：
  名称：

  环状尿素HIV-1蛋白酶抑制剂的立体异构体：合成和结合亲和力。

  摘要：

  我们已经合成了环状脲HIV-1蛋白酶抑制剂的立体异构体，以研究各种构型对结合亲和力的影响。使用四种不同的合成方法来制备所需的环状脲立体异构体。使用氨基酸起始原料的原始环状脲合成用于制备三种异构体。通过使用L-酒石酸和D-山梨糖醇作为手性原料的合成路线制备了三种另外的异构体。环状脲反式二醇的立体选择性羟基转化用于制备三种另外的异构体。共准备了10种可能的全部9种环状脲立体异构体，并描述了它们的结合亲和力。

  DOI：

  10.1021/jm980255b
• 作为产物：
  描述：

  (4R,5S,6S,7R)-hexahydro-5,6-bis[2-(trimethylsilyl)ethoxymethoxy]-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one 在 盐酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.5h， 生成 (4R,5S,6S,7R)-5,6-二羟基-1,3,4,7-四(苯基甲基)-1,3-二氮杂环庚-2-酮
  参考文献：
  名称：

  环状HIV蛋白酶抑制剂：合成，构象分析，P2 / P2'的结构活性关系和环状脲的分子识别。

  摘要：

  HIV-1蛋白酶（HIV-1PR）与拟肽抑制剂的复合物的高分辨率X射线结构揭示了结构水分子的存在，该结构水分子氢键合到酶的可移动侧翼和过渡过渡带两侧的两个羰基上态的抑制剂。利用C2对称二醇抑制剂的结构活性关系，计算机辅助药物设计工具和第一原理，我们设计并合成了新型的环状脲，其结合了该结构水并将侧链残基预先组织为最佳结合构象。构象分析表明对伪双轴苄基和伪二季基羟基取代基的偏爱和对RSSR立体化学的对映体偏爱。HIV-1PR和一种环状尿素DMP323的配合物的X射线和溶液NMR结构证实了结构水的置换。另外，结合的和“未结合的”（小分子X射线）配体具有相似的构象。提出了高度的预组织，互补性和水置换的熵增益，以解释这些小分子对酶的高度亲和力。小尺寸可能有助于在动物中观察到良好的口服生物利用度。基于结构优化的侧链填充酶的S2和S2'口袋产生了DMP323，该药物已在I期临床试验中进行了研究，但发现其

  DOI：

  10.1021/jm9602571

文献信息

• Design, Synthesis, and Evaluation of Tetrahydropyrimidinones as an Example of a General Approach to Nonpeptide HIV Protease Inhibitors
  作者：George V. De Lucca、Jing Liang、Paul E. Aldrich、Joe Calabrese、Beverly Cordova、Ronald M. Klabe、Marlene M. Rayner、Chong-Hwan Chang

  DOI：10.1021/jm970081i

  日期：1997.5.1

  Re-examination of the design of the cyclic urea class of HIV protease (HIVPR) inhibitors suggests a general approach to designing novel nonpeptide cyclic HIVPR inhibitors. This process involves the inversion of the stereochemical centers of the core transition-state isostere of the linear HIVPR inhibitors and cyclization of the resulting core using an appropriate cyclizing reagent. As an example, this

  对HIV蛋白酶（HIVPR）抑制剂的环状脲类设计的重新审查提出了设计新型非肽环状HIVPR抑制剂的一般方法。该过程涉及线性HIVPR抑制剂的核心过渡态等位体的立体化学中心的反转，以及使用合适的环化试剂环化所得核心。例如，该方法应用于HIVPR抑制剂的二氨基醇类，得到四氢嘧啶酮。四氢嘧啶酮的构象分析及其与HIVPR活性位点相互作用的模型表明，修饰导致了非常有效的HIVPR抑制剂（24种，Ki = 0.018 nM）。具有HIVPR的24配合物的X射线晶体学结构证实了分析和模型预测。
• Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
  申请人：Arimilli N. Murty

  公开号：US20070010489A1

  公开（公告）日：2007-01-11

  Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

  本发明揭示了具有HIV蛋白酶抑制剂性质的膦酸酯取代化合物，其具有作为治疗剂和其他工业用途的用途。该组合物抑制5型HIV蛋白酶活性和/或在治疗艾滋病和其他抗病毒感染方面具有治疗作用，以及在检测HIV蛋白酶方面的检测中有用。
• Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors
  作者：David A. Nugiel、Kim Jacobs、Tabitha Worley、Mona Patel、Robert F. Kaltenbach、Dayton T. Meyer、Prabhakar K. Jadhav、George V. De Lucca、Thomas E. Smyser、Ronald M. Klabe、Lee T. Bacheler、Marlene M. Rayner、Steven P. Seitz

  DOI：10.1021/jm960083n

  日期：1996.1.1

  A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.
• Grignard Addition to Aldonitrones. Stereochemical Aspects and Application to the Synthesis of C₂-Symmetric Diamino Alcohols and Diamino Diols
  作者：Alessandro Dondoni、Daniela Perrone、Marilisa Rinaldi

  DOI：10.1021/jo980980u

  日期：1998.12.1

  A new example of the stereoselective installation of the amino group at a saturated carbon center via organometallic addition of chiral aldehydes to nitrones is illustrated by the synthesis of 1,3-diamino propanol 1 and 1,4-diamino butandiol 2 units. Three diamino alcohol 1 stereotriads were obtained by stereoselective addition of alkylmagnesium halides (benzyl, cyclohexylmethyl, and metallyl) to the N-benzyl nitrones derived from beta-amino-alpha-hydroxy aldehydes followed by reduction of the resulting N-benzylhydroxylamines. Three 1,4-dibenzyl substituted stereoisomers of type 2 with fixed S configuration at C2 and C3 were prepared by sequential and simultaneous amination in two directions starting from L-threose nitrone and L-tartraldehyde bis-nitrone, respectively. The R,S,S,R isomer obtained by the former route was converted into a seven-membered ring cyclic urea (1,3-diazapin-2-one), i.e., a compound that belongs to a class of nonpeptide HIV-1 protease inhibitors.
• Stereospecific Synthesis, Structure−Activity Relationship, and Oral Bioavailability of Tetrahydropyrimidin-2-one HIV Protease Inhibitors
  作者：George V. De Lucca、Jing Liang、Indawati De Lucca

  DOI：10.1021/jm9803626

  日期：1999.1.1

  The use of tetrahydropyrimidinones as an alternate scaffold for designing HIVPR inhibitors has advantages, over the previously disclosed hexahydro-1,3-diazepin-2-ones, of being more unsymmetrical (different P1/P1'), less crystalline, more soluble, and more lipophilic (mono-ol vs diol). They show a better translation of K-i to IC90 for the more polar P2 groups that in general give the more potent enzyme inhibitors. Structure-activity relationship (SAR) studies of the tetrahydropyrimidinones showed that the phenylethyl P1' substituent, the hydroxyl group, and the urea carbonyl are all critical for good activity. However, there was significant flexibility in the possible P2/P2' substituents that could be used. Many analogues that contained identical or different P2/P2' substituents, or only one P2 substituent, were found to have excellent enzyme potency and several had excellent antiviral potency. Several of these compounds were examined for oral bioavailability in the rat or the dog at 10 mg/kg. However, the oral bioavailability of the tetrahydropyrimidinones was, in general, less than the corresponding hexahydro-1,3-diazepin-2-ones. Unfortunately, when all factors are considered, including potency, protein binding, solubility, bioavailability, and resistance profile, the tetrahydropyrimidinones did not offer any advantage over the previously disclosed hexahydro-1,3-diazepin-2-ones series.